NOW RECRUITING
Newly Diagnosed **FLT3-ITD (+) AML**
in Patients **aged 18 - 75**

QuANTUM-FIRST STUDY

Quizartinib **A**dvancement into the **N**ext Generation of **T**rials for **U**nmet Needs in A**M**L

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed **FLT3-ITD (+) Acute Myeloid Leukemia**



AML=acute myeloid leukemia; FLT-3=FMS-like tyrosine kinase 3; HSCT=hematopoietic stem cell transplant; ITD=internal tandem duplication;

* Cycle 1 consists of 7+3 regimen. Alternate dosing option for Cycle 2 can include a 5 + 2 regimen.

** Daunorubicin / Idarubicin

Primary Endpoint: Event-free Survival (EFS)

Secondary Endpoints:

- Overall Survival (OS)
- Complete Remission (CR)
- Composite Complete Remission (CRc)
- CR with no evidence of minimal residual disease (MRD)

Location: North America, Europe, Asia/Other Regions | **ClinicalTrials.gov Identifier:** NCT02668653

Quizartinib is an investigational agent and is not approved by the FDA or other regulatory agencies worldwide as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that quizartinib will become commercially available.

For more information about this clinical trial, please visit
www.clinicaltrials.gov/ct2/show/results/NCT02668653 or
www.QuantumFirstStudy.com

Daiichi-Sankyo
cancerenterprise

Care. Compassion. Science.
It's Our Obligation.

Printed in US 2017 PP-US-ON-0008 01/17 www.dsi.com